Vyome Debuts as HIND on Nasdaq, Strengthening US-India Innovation Ties

On India’s 79th Independence Day, Vyome Therapeutics, a homegrown pharma startup with international ambitions, marked a historic milestone by debuting on the Nasdaq Inventory Alternate below the ticker image HIND. The itemizing adopted its strategic merger with ReShape Lifesciences (Nasdaq: RSLS) and has develop into an emblem of India’s rising presence in international healthcare innovation.

A Defining Second for India’s World Rise

Vyome’s Independence Day debut carried deep symbolism. Because the Nasdaq Opening Bell rang in New York, it was greater than a company formality — it was a second of nationwide satisfaction, underscoring India’s ascent in scientific excellence and entrepreneurship.

Headquartered in Cambridge, Massachusetts and Delhi, Vyome operates throughout the US-India innovation hall, aiming to remodel affected person care in immuno-inflammatory and uncommon ailments. The corporate has positioned itself throughout the $100 billion immuno-inflammatory market by leveraging India’s cost-efficient R&D ecosystem alongside US-based innovation.

Vyome’s Historic Firsts

The itemizing cements Vyome’s place in historical past with a number of notable firsts:

• First firm from the Iron Pillar portfolio to go public.
• First IPO within the funding profession of founder-investor and Chairman Krishna Gupta, who beforehand oversaw a number of M&A exits.
• First Indian firm to ring the Nasdaq bell on India’s Independence Day.
• First India-origin IP-driven life sciences agency to listing on a serious US change.

“From Delhi to Nasdaq”

Co-founder Shiladitya Sengupta, a professor at Harvard Medical Faculty and researcher at MIT, described the milestone as a “journey from Delhi to Nasdaq.” He famous that it units a precedent for innovation-driven Indian pharma startups eyeing international markets.

CEO Venkat Nelabhotla referred to as the trail “lengthy and stuffed with challenges,” crediting the itemizing to the workforce’s dedication and affected person execution.

Monetary Construction and Possession

The merger, first introduced in December 2024, gave Vyome shareholders 91.62% possession within the mixed entity, whereas ReShape shareholders retained 8.38%. ReShape transferred most of its belongings (excluding money) and liabilities to UK-based Ninjour Well being Worldwide.

Nasdaq categorized the deal as a “change of management” transaction, requiring the brand new entity, now Vyome Holdings, Inc., to fulfill all preliminary itemizing necessities.

Importantly, Vyome enters the market utterly debt-free, some extent bolstered by Chairman Krishna Gupta, who emphasised the corporate’s concentrate on long-term shareholder worth.

Sleepless Nights, Occasions Sq. Celebrations

For buyers, the itemizing was each nerve-wracking and exhilarating. Mohanji Jolly, companion at Iron Pillar, shared on LinkedIn how the pre-listing jitters was a celebration on a Occasions Sq. rooftop with Indian snacks and sweets. “So exhilarating it left me sleepless for 2 nights,” he wrote.

Jolly framed the second as validation of the almost two-decade-old US-India innovation hall, constructed on belief and long-term dedication.

What’s Subsequent for Vyome

As Vyome Holdings begins buying and selling as HIND, the corporate goals to unlock worth in its clinical-stage belongings, develop its analysis pipeline, and strengthen collaborations throughout the US and India. Administration sees this as not only a monetary milestone however a platform for scaling Indian scientific innovation globally.